Advanced Cell Technology's Dr. Robert Lanza to Give Plenary, Keynote Address at the Translational Regenerative Medicine Forum
Worcester, MA - April 6, 2010 Advanced Cell Technology's (OTCBB: ACTC – News) Chief Scientific Officer, Robert Lanza, M.D., will be delivering the opening Plenary, Keynote Address at the inaugural 'Translational Regenerative Medicine Forum,' which will take place April 6-8, 2010, in Winston-Salem, North Carolina. Produced by the Regenerative Medicine Foundation, the meeting is designed to be the premiere international event for leaders in regenerative medicine translation, and the first of its kind to convene leaders from academic, research, clinical, regulatory, government, reimbursement and biotechnology industry interests.
Dr. Lanza will be delivering a presentation titled: "The Science: What's Next for the Clinic." His lecture will be followed in the afternoon by a plenary, Keynote address by Robert Klein, Chairman of the California Institute for Regenerative Medicine (CIRM), and Thursday morning by General Eric Schoomaker, Surgeon General of the United States.
A full-day media academy precedes the forum, in order to educate reporters and editors − including journalists from CNN, Scientific American, and WebMD − on the basics of regenerative medicine (stem cells sources, technologies, biomaterials) and pathways to deliver new therapies to patients. Dr. Lanza will be giving an opening lecture at the Academy titled "Stem Cells: Facts, Fallacies and the Unknown.” At the end of the Academy, Dr. Lanza will participate on the "The Future of Regenerative Medicine” Panel, Moderated by Maggie Fox with Reuters. The Panelists will share their thoughts on the following: What treatments are on the horizon and what scientific challenges need to be met to apply regenerative medicine technologies to even more conditions? What realistically can we expect in the next decade and beyond?
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.